Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Pieper

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
Circulation|February 22, 2001
Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studiesG I Barbash, Y Birnbaum, K Bogaerts, et al.
American Heart Journal|October 31, 2001
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximabM I Furman, D J Kereiakes, L A Krueger, et al.
Thrombosis Journal|April 8, 2020
Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registryJ Seelig, F W A Verheugt, M E W Hemels, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
Circulation|February 22, 2001
Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studiesG I Barbash, Y Birnbaum, K Bogaerts, et al.
American Heart Journal|October 31, 2001
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximabM I Furman, D J Kereiakes, L A Krueger, et al.
Thrombosis Journal|April 8, 2020
Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registryJ Seelig, F W A Verheugt, M E W Hemels, et al.
Pageof 9